Darolutamide

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 491 publications

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Journal: Future oncology (London, England)

Published: April 14, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

Journal: International journal of clinical oncology

Published: April 09, 2026

In Vitro and In Vivo Assessment of Darolutamide Encapsulated Lipid-Extruded PEGylated Liposomal Formulation.

In Vitro and In Vivo Assessment of Darolutamide Encapsulated Lipid-Extruded PEGylated Liposomal Formulation.

Journal: ACS applied bio materials

Published: April 08, 2026

Fatal Interstitial Pneumonitis During Combined Degarelix, Darolutamide, and Docetaxel Therapy for Metastatic Prostate Cancer.

Fatal Interstitial Pneumonitis During Combined Degarelix, Darolutamide, and Docetaxel Therapy for Metastatic Prostate Cancer.

Journal: Cureus

Published: March 09, 2026

LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients.

LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients.

Journal: International journal of molecular sciences

Published: March 04, 2026

ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy.

ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy.

Journal: European urology focus

Published: February 27, 2026

Bayesian interpretation of febrile neutropenia risk and primary granulocyte colony-stimulating factor prophylaxis during darolutamide triplet therapy.

Bayesian interpretation of febrile neutropenia risk and primary granulocyte colony-stimulating factor prophylaxis during darolutamide triplet therapy.

Journal: Japanese journal of clinical oncology

Published: February 22, 2026

Treatment of metastatic hormone-sensitive prostate cancer

Treatment of metastatic hormone-sensitive prostate cancer

Journal: Urologie (Heidelberg, Germany)

Published: February 13, 2026

Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial.

Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 04, 2026

Syndrome of Inappropriate Antidiuretic Hormone Secretion and Thrombotic Microangiopathy as Paraneoplastic Syndromes Complicating BRCA2-Mutated Metastatic Prostate Cancer.

Syndrome of Inappropriate Antidiuretic Hormone Secretion and Thrombotic Microangiopathy as Paraneoplastic Syndromes Complicating BRCA2-Mutated Metastatic Prostate Cancer.

Journal: Cureus

Published: January 10, 2026

Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study.

Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study.

Journal: Clinical genitourinary cancer

Published: January 10, 2026

Real-world Comparative Study of Androgen Receptor Signaling Inhibitors in Japanese Patients With Non-metastatic Castration-resistant Prostate Cancer.

Real-world Comparative Study of Androgen Receptor Signaling Inhibitors in Japanese Patients With Non-metastatic Castration-resistant Prostate Cancer.

Journal: Anticancer research

Published: January 03, 2026

Showing 1-12 of 491

Last Updated: 04/28/2026